LinkedIn
WebsiteIntroduction
XENETIC BIOSCIENCES INC (NASDAQ: XBIO), headquartered in Framingham, Massachusetts, is a biopharmaceutical company focused on advancing immune-oncology technologies for hard-to-treat cancers. The company’s proprietary DNase platform targets neutrophil extracellular traps (NETs), which are implicated in both cancer progression and resistance to chemotherapy, checkpoint inhibitors, and radiotherapy. Additionally, Xenetic is developing XCART®, a personalized CAR T platform engineered against patient- and tumor-specific neoantigens, and PolyXen™, a drug-delivery system designed to extend the half-life and improve the pharmacological properties of biologic therapies.
Corporate Structure and Leadership
Employees: 11–50 (per company disclosures)
Key executives include:
- James F. Parslow, Interim Chief Executive Officer and Chief Financial Officer, brings over 35 years of strategic and financial leadership in the biotech and clean-tech sectors.
- Scott N. Cullison, Executive Consultant for Business Development, with more than two decades of experience in the pharmaceutical and biotech industries.
- Reid P. Bissonnette, Ph.D., Executive Consultant for Translational Research and Development, has over 25 years of experience in oncology and immuno-oncology drug discovery.
Biopharmaceuticals by little plant
Recent Developments and News
- In September 2025, PeriNess Ltd. announced that Bnei Zion Medical Center initiated patient dosing in a Phase I study combining systemic DNase I with FOLFIRINOX as a first-line treatment for unresectable, locally advanced, or metastatic pancreatic carcinoma.
- LinkedIn updates in October 2025 highlighted Dr. Reid Bissonnette’s role in advancing translational research and development, and noted that degradation of NETs by DNase I may contribute to maintaining CAR T-cell function.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (2025-10-08) | $13.19 |
| Price Change | +207.46 percent |
| Trading Volume | 6,236,377 |
| Exchange | NASDAQ |
As of October 8, 2025, Xenetic’s stock price increased by 207.46 percent in the year-to-date period. The company maintains an exclusive license agreement with Takeda Pharmaceuticals regarding coagulation disorders, which may provide a potential royalty stream. Its strategic priorities include advancing the systemic DNase program into clinical trials for pancreatic and other solid tumors, progressing XCART® cell therapies for B-cell lymphomas, and collaborating with third parties to enhance the application of PolyXen™ across next-generation biologics.
Market Position and Industry Context
In the U.S. oncology market, pancreatic cancer is the third leading cause of cancer-related deaths, with approximately 62,000 new cases and 50,000 fatalities annually. Xenetic’s focus on NETs addresses a significant concern in solid tumors and immuno-oncology. Its CAR T and drug-delivery platforms position the company within the areas of personalized cell therapy and improved biologic performance, sectors that are attracting investment and collaboration activity across the biotech industry.
tl;dr
As of October 8, 2025, XBIO shares trade at $13.19, reflecting an increase of 207.46 percent year-to-date on NASDAQ. In September 2025, Bnei Zion Medical Center began dosing patients in a Phase I trial of systemic DNase I plus FOLFIRINOX for pancreatic carcinoma under a collaboration with PeriNess. The company is advancing its DNase and XCART® programs, supported by an exclusive Takeda license for PolyXen™ and a leadership team with extensive experience in oncology and commercialization.
